Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Vor Biopharma Inc. has received a consensus rating of "Hold" from eleven research firms, with one sell, five hold, and five buy recommendations.
• The average 12-month price objective for Vor Biopharma is $113.83, but shares have recently traded down to around $31.23.
• Insiders have sold over 1 million shares of Vor Biopharma stock in the last three months, reflecting a 3.43% decrease in their ownership.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) has been assigned an average rating of "Hold" from the eleven research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $113.8333.

A number of analysts have recently issued reports on VOR shares. Wall Street Zen lowered Vor Biopharma to a "strong sell" rating in a research report on Saturday, June 28th. Wedbush reaffirmed an "outperform" rating on shares of Vor Biopharma in a research report on Thursday, June 26th. Zacks Research raised Vor Biopharma from a "strong sell" rating to a "hold" rating in a research report on Wednesday, September 10th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vor Biopharma in a research report on Wednesday, October 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $60.00 target price on shares of Vor Biopharma in a research report on Thursday, August 14th.

Vor Biopharma Trading Down 1.5%

Shares of NASDAQ VOR opened at $31.23 on Monday. The firm has a fifty day moving average of $37.73. The firm has a market cap of $214.05 million, a P/E ratio of -0.11 and a beta of 2.07. Vor Biopharma has a 12-month low of $2.62 and a 12-month high of $65.80.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($43.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($11.40) by ($32.20).

Insiders Place Their Bets

In related news, major shareholder Reprogrammed Interchange Llc sold 48,884 shares of the business's stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $32.07, for a total value of $1,567,709.88. Following the completion of the sale, the insider directly owned 1,374,775 shares of the company's stock, valued at $44,089,034.25. The trade was a 3.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold 1,021,203 shares of company stock valued at $21,890,146 over the last three months. 0.45% of the stock is owned by insiders.

Institutional Trading of Vor Biopharma

Several hedge funds and other institutional investors have recently bought and sold shares of the company. XTX Topco Ltd bought a new stake in Vor Biopharma in the second quarter valued at about $66,000. Goldman Sachs Group Inc. increased its holdings in Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after buying an additional 58,247 shares during the last quarter. Jane Street Group LLC bought a new stake in Vor Biopharma in the first quarter valued at about $140,000. OMERS ADMINISTRATION Corp bought a new stake in Vor Biopharma in the first quarter valued at about $100,000. Finally, Money Concepts Capital Corp increased its holdings in Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after buying an additional 26,535 shares during the last quarter. 97.29% of the stock is owned by institutional investors.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.